Entourage Effect: Full-Spectrum Vs. Isolate
Beyond CBD: A Fuller Range Of Benefits
What is the Entourage Effect and why should you choose Full-Spectrum CBD? First off, CBD by itself is pretty awesome. But using only CBD may mean missing out on the full benefits found in real Full-Spectrum CBD.
In this guide, we’ll explain the benefits of Full-Spectrum CBD vs. Isolate CBD and what makes a real Full-Spectrum product. We’ll also explain how you can naturally enhance your CBD experience for the most effective relief.
Why Real Full-Spectrum Matters
There’s over 100 different cannabinoids found in hemp, each with their own unique health benefits!
While CBD & THC are the most common, there’s also cannabinoids like CBDV, CBG, THCV, CBN, CBC, and etc. Each cannabinoid has its own unique benefits which you might not get by only having CBD & THC – which most brands only have in their “full-spectrum” products.
This is why real Full-Spectrum products matter, as they should have the widest range of cannabinoids for us to get the most complete range of health benefits from CBD products.
Compared to a formula with only CBD & THC, a real Full-Spectrum formula with CBD, CBG, CBDV & THCV will have more potential benefits and be more effective for pain, anxiety, sleep or whatever ailment you are hoping to relieve.
What are the benefits of other Cannabinoids?
While CBD can help improve sleep, chronic pain and anxiety, it may not be as effective as other cannabinoids such as a Full-Spectrum formula with CBG, CBDV, or THCV may be for certain ailments.
For Gut Health & Pain
CBG may offer powerful antibacterial and anti-inflammatory properties, which could benefit issues such as IBS, colitis and acne. It may also have benefits for those with severe pain and muscle/joint inflammation or arthritis.
For Skincare & Braincare
CBDV may be highly effective as an anti-acne agent and could have powerful neuroprotective effects for those suffering from nausea or epilepsy. CBDV may also have benefits for those suffering from headaches or chronic nerve pain.
Anxiety Relief & Focus
(Non-Psychoactive)
THCV is a rare and exclusive cannabinoid that may be a greater anxiety suppressant than CBD, with potential benefits for appetite management and for boosting mental clarity. THCV functions like the exact opposite of THC, actually working to block receptors that respond to THC. THCV is completely non-psychoactive and so it cannot get you high.
Cannabinoids Are Kind of Like Vitamins..
A balanced and healthy diet means having a variety of vitamins and nutrients for the widest range of health benefits. We don’t aim to have just one vitamin or mineral.
A balanced diet also means having a variety of cannabinoids for the greatest range of benefits – which means using a full-spectrum CBD formula. Having multiple cannabinoids together can also create a synergestic “Entourage Effect.”
What is the Entourage Effect?
When you mix CBD, CBG, CBDV, THCV and more together..
When cannabinoids are taken together, they can enhance the effects of each other. This is called the Entourage Effect. Cannabinoids are also enhanced by other plant compounds such as terpenes (smell & flavour compounds found in fruits).
When taken together (like in real Full-Spectrum CBD), Cannabinoids & Terpenes can create a powerful synergestic entourage effect by:
- Amplifying the effects of each other.
- Balancing out the negative effects of each other.
- Making up for what the other is lacking in benefits.
CBD & THC – Balancing Out the Negatives
THC by itself has many benefits, but it’s also linked to negative effects such as increased anxiety, risk of psychosis, increased depression, and of course increased appetite. Long-term use of THC has also been linked to reduced concentration, decreased short-term memory and impaired motor skills.
In nature, THC doesn’t normally occur by itself. Rather, THC usually comes with CBD in wild cannabis & hemp plants. It’s this CBD that helps counteract the negative effects of THC such as anxiety and paranoia – effectively “balancing it out” while still allowing you to have the positive effects of THC’s pain relief. This is a clear case of the entourage effect happening in nature!
THC & THCV – Removing the Negatives & Enhancing the Positives
THCV is a unique and rare cannabinoid that actually has the opposite effects of THC. When combined with THC, THCV can reduce the negatives of THC while enhancing the positives of it.
By using THCV with THC you can reduce the anxiety & hunger of THC, while enhancing the creative energy of THC by boosting your energy & focus, decreasing your appetite, and reducing your anxiety. THCV may also have powerful neuroprotective benefits for Parkinson’s, anti-psychotic effects and promise as an anti-acne agent.
CBD, CBG, CBDV & THCV – Complimenting the Strengths of Each Other
CBD, CBG, CBDV & THCV. Each cannabinoid may be best in one particular area. CBD is all-around great for sleep, pain & anxiety. CBG may be a greater anti-inflammatory than CBD and may be beneficial for IBS/digestive issues. CBDV may be best for skincare & braincare. THCV may be best for boosting your energy, focus and reducing your anxiety. When taken together, having CBD, CBG, CBDV & THCV gives you the perfect overall formula for the most complete range of benefits.
Enhance Your CBD with Fruits & Vegetables!
The Entourage Effect – Synergize With Terpenes
But wait there’s more! In addition to cannabinoids, there are compounds known as terpenes that can enhance the entourage effect of Full-Spectrum CBD.
Where can you find them? They’re right In your kitchen!
Terpenes are the taste and smell compounds in fruits, vegetables and flowers. Terpenes are why lemons taste and smells like lemons, and why strawberries taste and smell like strawberries. Terpenes are naturally produced in plants and may have direct, synergistic benefits when combined with cannabinoids in Full-Spectrum CBD.
Three common household terpenes include caryophyllene, limonene and myrcene.
Caryophyllene is found in herbs and spices like black pepper, basil, oregano and of course in cannabis. It’s that spicey, powerful scent that gives pepper its kick. Caryophyllene has been suggested to have anti-anxiety, anti-inflammatory and antioxidant effects.
Limonene is responsible for the distinct, citrus smell in fruits like lemons, oranges and limes and in cannabis strains like Lemon Haze. Limonene has been suggested to have anti-inflammatory, anti-anxiety, pain-relief, relaxative and antioxidant effects.
Myrcene is responsible for the sweet, tangy smell of fruits like mangoes and nectarines. Myrcene can also be found in plants like bay leaves, hops, lemon grass, basil and rosemary. Myrcene has the synergistic effect of enhancing and strengthening the effect of THC, as it “allows more THC to reach brain cells.” Myrcene has also been suggested to have anti-pain, anti-inflammatory and sleep benefits.
In conclusion, by supplementing your Full-Spectrum CBD with natural foods, you can help boost your Entourage Effect with common terpenes found in your kitchen.
How Can I Experience the Entourage Effect?
Made in BC with all-natural ingredients, our Premium Full-Spectrum Oil Tincture delivers a revolutionary blend of CBD, CBG, CBDV and THCV for the most potent entourage effect for the most complete range of benefits.
Unmatched, Real Full-Spectrum CBD
Other brands simply don’t match our Full-Spectrum Formula, as most only have CBD & THC in their “full-spectrum CBD” vs. CBDNorth’s Full-Spectrum Complex with CBD, CBG, CBDV & THCV.
So if you’re looking to have the most potent entourage effect (that only comes from real Full-Spectrum CBD) our premium oil tincture is the perfect option for you.
Shop Canada’s
Best Full-Spectrum.
$42.24 – $149.49
References:
CBD – (Click for CBD Guide)
Mandolini, G. M., Lazzaretti, M., Pigoni, A., Oldani, L., Delvecchio, G., & Brambilla, P. (2018). Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiology and psychiatric sciences, 1-9.
https://www.ncbi.nlm.nih.gov/pubmed/26260390
Mücke, M., Phillips, T., Radbruch, L., Petzke, F., & Häuser, W. (2018). Cannabis‐based medicines for chronic neuropathic pain in adults. The Cochrane Library.
https://www.ncbi.nlm.nih.gov/pubmed/29513392
Jensen, B., Chen, J., Furnish, T., & Wallace, M. (2015). Medical marijuana and chronic pain: a review of basic science and clinical evidence. Current pain and headache reports, 19(10), 50.
https://www.ncbi.nlm.nih.gov/pubmed/26325482
Burns, T. L., & Ineck, J. R. (2006). Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Annals of Pharmacotherapy, 40(2), 251-260.
https://www.ncbi.nlm.nih.gov/pubmed/16449552
Brunt, T. M., van Genugten, M., Höner-Snoeken, K., van de Velde, M. J., & Niesink, R. J. (2014). Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis. Journal of clinical psychopharmacology, 34(3), 344-349.
Babson, K. A., Sottile, J., & Morabito, D. (2017). Cannabis, cannabinoids, and sleep: a review of the literature. Current psychiatry reports, 19(4), 23.
https://www.ncbi.nlm.nih.gov/pubmed/28349316
Fitzcharles, M. A., Baerwald, C., Ablin, J., & Häuser, W. (2016). Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis). Der Schmerz, 30(1), 47-61.
Iskedjian, M., Bereza, B., Gordon, A., Piwko, C., & Einarson, T. R. (2007). Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Current medical research and opinion, 23(1), 17-24.
https://www.ncbi.nlm.nih.gov/books/NBK74699/
Lakhan, S. E., & Rowland, M. (2009). Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC neurology, 9(1), 59.
https://www.ncbi.nlm.nih.gov/pubmed/19961570
Wade, D. T., Collin, C., Stott, C., & Duncombe, P. (2010). Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Multiple Sclerosis Journal, 16(6), 707-714.
https://www.ncbi.nlm.nih.gov/pubmed/20558502
Wright, S., Duncombe, P., & Altman, D. G. (2012). Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach. Trials, 13(1), 189.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487910/
McPartland, J. M., Guy, G. W., & Di Marzo, V. (2014). Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PloS one, 9(3), e89566.
Cuba, L. F., Salum, F. G., Cherubini, K., & Figueiredo, M. A. Z. (2017). Cannabidiol: an alternative therapeutic agent for oral mucositis?. Journal of clinical pharmacy and therapeutics, 42(3), 245-250.
https://www.ncbi.nlm.nih.gov/pubmed/28191662
Martin-Santos, R., Fagundo, A. B., Crippa, J. A., Atakan, Z., Bhattacharyya, S., Allen, P., … & McGuire, P. (2010). Neuroimaging in cannabis use: a systematic review of the literature. Psychological medicine, 40(3), 383-398.
https://www.ncbi.nlm.nih.gov/pubmed/19627647
Ashton, C. H., Moore, P. B., Gallagher, P., & Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology, 19(3), 293-300.
Iseger TA, Bossong MG (March 2015). “A systematic review of the antipsychotic properties of cannabidiol in humans”. Schizophrenia Research. 162 (1–3): 153–61.
https://www.ncbi.nlm.nih.gov/pubmed/25667194
Iseger, T. A., & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia research, 162(1-3), 153-161.
https://www.ncbi.nlm.nih.gov/pubmed/25667194
Bostwick, J. M. (2012, February). Blurred boundaries: the therapeutics and politics of medical marijuana. In Mayo Clinic Proceedings (Vol. 87, No. 2, pp. 172-186). Elsevier.
Couch, D. G., Maudslay, H., Doleman, B., Lund, J. N., & O’Sullivan, S. E. (2018). The use of cannabinoids in colitis: a systematic review and meta-analysis. Inflammatory bowel diseases, 24(4), 680-697.
Stockings, E., Zagic, D., Campbell, G., Weier, M., Hall, W. D., Nielsen, S., … & Degenhardt, L. (2018). Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry, 89(7), 741-753.
https://www.ncbi.nlm.nih.gov/pubmed/29511052
Reddy, D. S., & Golub, V. M. (2016). The pharmacological basis of cannabis therapy for epilepsy. Journal of Pharmacology and Experimental Therapeutics, 357(1), 45-55.
Sultan, S. R., Millar, S. A., England, T. J., & O’Sullivan, S. E. (2017). A systematic review and meta-analysis of the haemodynamic effects of Cannabidiol. Frontiers in pharmacology, 8, 81.
Hurd, Y. L., Yoon, M., Manini, A. F., Hernandez, S., Olmedo, R., Ostman, M., & Jutras-Aswad, D. (2015). Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics, 12(4), 807-815.
https://www.ncbi.nlm.nih.gov/pubmed/26269227
Prud’homme, M., Cata, R., & Jutras-Aswad, D. (2015). Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Substance abuse: research and treatment, 9, SART-S25081.
Marco, E. M., García-Gutiérrez, M. S., Bermúdez-Silva, F. J., Moreira, F., Guimarães, F., Manzanares, J., & Viveros, M. P. (2011). Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. Frontiers in behavioral neuroscience, 5, 63.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186912/
Zhornitsky, S., & Potvin, S. (2012). Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals, 5(5), 529-552.
https://www.ncbi.nlm.nih.gov/pubmed/24281562
Crippa, J. A., Derenusson, G. N., Chagas, M. H., Atakan, Z., Martín-Santos, R., Zuardi, A. W., & Hallak, J. E. (2012). Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm reduction journal, 9(1), 7.
Stern, C. A., Gazarini, L., Takahashi, R. N., Guimaraes, F. S., & Bertoglio, L. J. (2012). On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacology, 37(9), 2132.
Liou, G. I. (2010). Diabetic retinopathy: role of inflammation and potential therapies for anti-inflammation. World journal of diabetes, 1(1), 12.
Le Foll, B., Trigo, J. M., Sharkey, K. A., & Le Strat, Y. (2013). Cannabis and Δ 9-tetrahydrocannabinol (THC) for weight loss?. Medical hypotheses, 80(5), 564-567.
CBG – (Click for CBG Guide)
Couch, D. G., Maudslay, H., Doleman, B., Lund, J. N., & O’Sullivan, S. E. (2018). The use of cannabinoids in colitis: a systematic review and meta-analysis. Inflammatory bowel diseases, 24(4), 680-697.
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., … & Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical pharmacology, 85(9), 1306-1316.
Giacoppo, S., Gugliandolo, A., Trubiani, O., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2017). Cannabinoid CB2 receptors are involved in the protection of RAW264. 7 macrophages against the oxidative stress: an in vitro study. European journal of histochemistry: EJH, 61(1).
https://www.ncbi.nlm.nih.gov/pubmed/27094344
Pucci, M., Rapino, C., Di Francesco, A., Dainese, E., D’addario, C., & Maccarrone, M. (2013). Epigenetic control of skin differentiation genes by phytocannabinoids. British journal of pharmacology, 170(3), 581-591.
Fernández-Ruiz, J; Moro, M. A; Martínez-Orgado, J (2015). “Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications”. Neurotherapeutics. 12 (4): 793–806. doi:10.1007/s13311-015-0381-7
https://www.ncbi.nlm.nih.gov/pubmed/26260390
Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., Muñoz, E., & Sagredo, O. (2015). Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 12(1), 185-199.
Smeriglio, A., Giofrè, S. V., Galati, E. M., Monforte, M. T., Cicero, N., D’Angelo, V., … & Circosta, C. (2018). Inhibition of aldose reductase activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol. Fitoterapia, 127, 101-108.
Giacoppo, S., Gugliandolo, A., Trubiani, O., Pollastro, F., Grassi, G., Bramanti, P., & Mazzon, E. (2017). Cannabinoid CB2 receptors are involved in the protection of RAW264. 7 macrophages against the oxidative stress: an in vitro study. European journal of histochemistry: EJH, 61(1).
Appendino, G., Gibbons, S., Giana, A., Pagani, A., Grassi, G., Stavri, M., … & Rahman, M. M. (2008). Antibacterial cannabinoids from Cannabis sativa: a structure− activity study. Journal of natural products, 71(8), 1427-1430.
Wilkinson, J. D., & Williamson, E. M. (2007). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of dermatological science, 45(2), 87-92.
Colasanti, B. K., Craig, C. R., & Allara, R. D. (1984). Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol. Experimental eye research, 39(3), 251-259.
Baek, S. H., Kim, Y. O., Kwag, J. S., Choi, K. E., & Jung, W. Y. (1998). Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Archives of pharmacal research, 21(3), 353.
https://www.ncbi.nlm.nih.gov/pubmed/9875457
Borrelli, F., Pagano, E., Romano, B., Panzera, S., Maiello, F., Coppola, D., … & Izzo, A. A. (2014). Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid. Carcinogenesis, 35(12), 2787-2797.
THCV – (Click for THCV Guide)
O’brien, L. D., Wills, K. L., Segsworth, B., Dashney, B., Rock, E. M., Limebeer, C. L., & Parker, L. A. (2013). Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability. Pharmacology Biochemistry and Behavior, 103(3), 597-602.
Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., … & Tan, G. D. (2016). Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care, dc160650.
https://www.ncbi.nlm.nih.gov/pubmed/27573936
Horváth, B., Mukhopadhyay, P., Haskó, G., & Pacher, P. (2012). The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. The American journal of pathology, 180(2), 432-442.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349875/
Wargent, E. T., Zaibi, M. S., Silvestri, C., Hislop, D. C., Stocker, C. J., Stott, C. G., … & Cawthorne, M. A. (2013). The cannabinoid Δ 9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutrition & diabetes, 3(5), e68.
Deiana, S., Watanabe, A., Yamasaki, Y., Amada, N., Arthur, M., Fleming, S., … & Platt, B. (2012). Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour. Psychopharmacology, 219(3), 859-873.
García C, Palomo-Garo C, García-Arencibia M, Ramos J, Pertwee R, Fernández-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson’s disease. British Journal of Pharmacology. 2011;163(7):1495-1506. doi:10.1111/j.1476-5381.2011.01278.x.
Thomas, A., Stevenson, L. A., Wease, K. N., Price, M. R., Baillie, G., Ross, R. A., & Pertwee, R. G. (2005). Evidence that the plant cannabinoid Δ9‐tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. British journal of pharmacology, 146(7), 917-926.
https://www.ncbi.nlm.nih.gov/pubmed/16205722
Pertwee, R. G., Thomas, A., Stevenson, L. A., Ross, R. A., Varvel, S. A., Lichtman, A. H., … & Razdan, R. K. (2007). The psychoactive plant cannabinoid, Δ9‐tetrahydrocannabinol, is antagonized by Δ8‐and Δ9‐tetrahydrocannabivarin in mice in vivo. British journal of pharmacology, 150(5), 586-594.
https://www.ncbi.nlm.nih.gov/pubmed/17245367
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin. British journal of pharmacology, 153(2), 199-215.
https://www.ncbi.nlm.nih.gov/pubmed/17828291
Ma, Y. L., Weston, S. E., Whalley, B. J., & Stephens, G. J. (2008). The phytocannabinoid Δ9‐tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. British journal of pharmacology, 154(1), 204-215.
Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V., & Mechoulam, R. (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in pharmacological sciences, 30(10), 515-527.
https://www.ncbi.nlm.nih.gov/pubmed/19729208
Hill, A. J., Weston, S. E., Jones, N. A., Smith, I., Bevan, S. A., Williamson, E. M., … & Whalley, B. J. (2010). Δ9‐Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats. Epilepsia, 51(8), 1522-1532.
Bátkai, S., Mukhopadhyay, P., Horváth, B., Rajesh, M., Gao, R. Y., Mahadevan, A., … & Maccarrone, M. (2012). Δ8‐Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors. British journal of pharmacology, 165(8), 2450-2461.
https://www.ncbi.nlm.nih.gov/pubmed/21470208
Bolognini, D., Costa, B., Maione, S., Comelli, F., Marini, P., Di Marzo, V., … & Pertwee, R. G. (2010). The plant cannabinoid Δ9‐tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. British journal of pharmacology, 160(3), 677-687.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & therapeutics, 133(1), 79-97.
Cascio, M. G., Zamberletti, E., Marini, P., Parolaro, D., & Pertwee, R. G. (2015). The phytocannabinoid, Δ9‐tetrahydrocannabivarin, can act through 5‐HT1A receptors to produce antipsychotic effects. British journal of pharmacology, 172(5), 1305-1318.
Oláh, A., Markovics, A., Szabó‐Papp, J., Szabó, P. T., Stott, C., Zouboulis, C. C., & Bíró, T. (2016). Differential effectiveness of selected non‐psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Experimental dermatology, 25(9), 701-707.
CBDV – (Click for CBDV Guide)
Amada N, Yamasaki Y, Williams CM, Whalley BJ (2013). “Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression”. PeerJ. 1: e214. doi:10.7717/peerj.214
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840466/
Iannotti, F. A., Hill, C. L., Leo, A., Alhusaini, A., Soubrane, C., Mazzarella, E., … & Stephens, G. J. (2014). Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS chemical neuroscience, 5(11), 1131-1141.
https://www.ncbi.nlm.nih.gov/pubmed/25029033
Hill, A. J., Mercier, M. S., Hill, T. D. M., Glyn, S. E., Jones, N. A., Yamasaki, Y., … & Williams, C. M. (2012). Cannabidivarin is anticonvulsant in mouse and rat. British journal of pharmacology, 167(8), 1629-1642.
https://www.ncbi.nlm.nih.gov/pubmed/22970845
Rosenberg, E. C., Patra, P. H., & Whalley, B. J. (2017). Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy & Behavior, 70, 319-327.
https://www.ncbi.nlm.nih.gov/pubmed/28190698
Gaston, T. E., & Friedman, D. (2017). Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy & Behavior, 70, 313-318.
https://www.ncbi.nlm.nih.gov/pubmed/28087250
Hill, T. D. M., Cascio, M. G., Romano, B., Duncan, M., Pertwee, R. G., Williams, C. M., … & Hill, A. J. (2013). Cannabidivarin‐rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor‐independent mechanism. British journal of pharmacology, 170(3), 679-692.
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015). Cannabinoids and epilepsy. Neurotherapeutics, 12(4), 747-768.
Oláh, A., Markovics, A., Szabó‐Papp, J., Szabó, P. T., Stott, C., Zouboulis, C. C., & Bíró, T. (2016). Differential effectiveness of selected non‐psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Experimental dermatology, 25(9), 701-707.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012). Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology & therapeutics, 133(1), 79-97.
CBDNorth – Best Selling CBD Products 2024
CBD Oil Canada | CBD Gummies Canada |
Full Spectrum CBD Oil Canada | CBD Oil for Dogs Canada |
CBD Dog Treats Canada | CBD Cream Canada |
CBN For Sleep Canada | CBD Oil for Cats Canada |
Comments are closed.